BackAvid Bioservices Overview

Avid Bioservices Other Current Assets

Track Avid Bioservices's other current assets ($4.8M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$4.80M
51.84% YoYΔ $-5.17M vs prior year quarter

Peer average / median

Loading

Avid Bioservices Other Current Assets History

Loading

Avid Bioservices vs. peers: Other Current Assets Comparison

Loading

Avid Bioservices Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Avid Bioservices (CDMO) FAQ

Avid Bioservices (CDMO) currently reports a other current assets of $4.8M as of October 2024. That compares with $10M in the prior-year period — down 51.8% year over year. Use the charts on this page to explore Avid Bioservices's other current assets history and peer comparisons.

Avid Bioservices's other current assets decreased from $10M to $4.8M — a 51.8% year-over-year decrease (period ending October 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Avid Bioservices reported $4.8M in other current assets as of October 2024. That compares with $10M in the prior-year period — down 51.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current assets of $4.8M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Avid Bioservices, and consider following CDMO for alerts when major investors trade the stock.

Avid Bioservices is classified in the Healthcare sector. On other current assets, it currently shows $4.8M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CDMO with unrelated industries.